Tuesday 23 Apr 2024
By
main news image

KUALA LUMPUR (Nov 4): Kenanga IB Research has initiated coverage on Pharmaniaga Holdings Bhd at RM4.60 with an Outperform rating and target price of RM5.35, which it said was based on 14.5x FY15 EPS, which is at 15% premium to Pharmaniaga’s peers’ average due to its bigger market capitalisation.

In a note Tuesday, the research house said Pharmaniaga was a GLC-linked company with the sole concession holder to purchase, store, supply and distribute approved drugs and medical products to 148 government hospitals and 1,400 clinics and district offices nationwide.

“We like Pharmaniaga because of: (i) its defensive earnings being a prime beneficiary being the sole concession holder to purchase, store, supplies and distribute approved drugs and medical products to Government hospitals and clinics nationwide, (ii) its growth exposure in the healthcare and pharmaceuticals industry supported by an ageing population, and (iii) decent dividend yield of 4.8%,” said Kenanga IB Research.

      Print
      Text Size
      Share